Ossica

Active Ingredient:: Ibandronate Sodium Hydrate
Origin:: EU

Ossica (Ibandronate Sodium Hydrate)

Q: What is Ossica used for?

Ossica contains ibandronate sodium hydrate, a bisphosphonate indicated for the prevention and treatment of osteoporosis in postmenopausal women and in men who are at high risk of fracture. It helps reduce bone loss and lower the likelihood of fractures.

Q: How does ibandronate sodium hydrate work?

Ibandronate sodium hydrate binds to bone mineral surfaces and is taken up by osteoclasts during bone resorption. It inhibits the mevalonate pathway, causing osteoclast apoptosis and thereby decreasing bone resorption, which helps maintain bone density.

Q: What is the usual dose of Ossica?

The specific dose and infusion schedule are determined by the prescribing physician based on the patient’s clinical condition, renal function, and treatment goals. Dosage details are provided in the product’s prescribing information.

Q: Is Ossica safe during pregnancy or breastfeeding?

The safety of ibandronate sodium hydrate in pregnancy or while breastfeeding has not been established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and this decision must be made by a qualified healthcare professional.

Q: How do I order Ossica from GNH India?

To request Ossica, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Q: How does Ossica compare with other osteoporosis treatments?

Ossica is an intravenous bisphosphonate, offering a convenient once‑yearly or once‑every‑three‑months dosing schedule compared with oral bisphosphonates that require weekly or monthly dosing. It provides rapid suppression of bone turnover, but like all bisphosphonates, it shares similar safety considerations such as renal monitoring and rare risks of jaw osteonecrosis.

Q: What are the storage and handling requirements for Ossica?

Ossica should be stored at ambient temperature, protected from light and moisture, and kept in its original packaging until use. Do not freeze the solution, and ensure the vial is inspected for particulate matter before administration.

Q: How is Ossica administered?

Ossica is given as an intravenous infusion over a short period, typically 15‑30 minutes, under the supervision of a qualified healthcare professional. The infusion rate and total volume are defined in the prescribing information and must be followed precisely.

Q: What are the most serious risks associated with Ossica?

Serious risks include osteonecrosis of the jaw, atypical femoral fractures, severe hypocalcemia, acute renal impairment, and rare hypersensitivity reactions. Patients should be monitored for signs of these conditions, and appropriate preventive measures such as dental assessment and renal function testing are recommended.

Q: Who should not use Ossica?

Ossica is contraindicated in patients with severe renal impairment (creatinine clearance <30 mL/min), known hypersensitivity to ibandronate or any component of the formulation, and those with existing osteonecrosis of the jaw. Caution is advised for patients with uncontrolled hypocalcemia or active dental problems.

Ibandronate Sodium Hydrate, the active ingredient in Ossica, is a bisphosphonate presented as an intravenous solution for intravenous use. It is indicated for the prevention and treatment of osteoporosis in postmenopausal women and for men at high risk of fracture. The drug works by reducing bone resorption, helping maintain bone density and lower fracture risk.

GNH India supplies Ossica as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Gedeon Richter Plc.

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Ossica (ibandronate sodium hydrate) is used in the management of osteoporosis, a condition characterized by reduced bone mass and increased fracture risk.

Postmenopausal osteoporosis: reduces the risk of vertebral and non‑vertebral fractures.
Male osteoporosis at high risk of fracture: improves bone mineral density and lowers fracture incidence.
Osteoporosis prevention: administered to reduce bone loss in individuals at risk of developing osteoporosis.

How It Works

Ibandronate sodium hydrate binds to hydroxyapatite crystals on bone surfaces, where it is taken up by osteoclasts during bone resorption. The drug inhibits the mevalonate pathway within osteoclasts, leading to apoptosis and a marked reduction in bone resorption, thereby helping to preserve bone mass and strength.

Side Effects

Common Side Effects

Acute phase reaction: fever, chills, myalgia, and headache occurring within 24‑48 hours after infusion.
Nausea or vomiting.
Transient flu‑like symptoms.
Injection site discomfort or erythema.
Arthralgia or joint stiffness.
Elevated serum creatinine (mild).

Serious or Rare Side Effects

Osteonecrosis of the jaw (ONJ).
Atypical femoral fractures.
Severe hypocalcemia.
Acute renal failure or significant decline in renal function.
Anaphylactic or severe hypersensitivity reactions.
Atrial fibrillation or other serious cardiac events.

Precautions & Warnings

Before initiating therapy, consider the following precautions:

Assess renal function: avoid use if creatinine clearance is <30 mL/min.
Monitor serum calcium: correct hypocalcemia before infusion.
Ensure adequate vitamin D and calcium intake to support bone health.
Review concomitant nephrotoxic medications and adjust as needed.
Use with caution in patients with a history of cardiac arrhythmia.
Store at ambient temperature: keep in the original container, protect from light and moisture.

Avoid Interactions

Ibandronate sodium hydrate may interact with several agents:

Major Interactions (Avoid)

Concurrent intravenous bisphosphonates: increased risk of renal toxicity.
High‑dose intravenous contrast agents: may exacerbate renal impairment.
Severe renal impairment (creatinine clearance <30 mL/min): contraindicated.

Moderate Interactions (Monitor Closely)

Calcium, magnesium, or antacid supplements given simultaneously: may reduce drug efficacy; separate administration by at least 4 hours.
Atrial fibrillation‑prone patients: monitor cardiac rhythm during therapy.
Hypocalcemia‑inducing drugs (e.g., loop diuretics): monitor serum calcium levels.

Frequently Asked Questions

Ossica contains ibandronate sodium hydrate, a bisphosphonate indicated for the prevention and treatment of osteoporosis in postmenopausal women and in men who are at high risk of fracture. It helps reduce bone loss and lower the likelihood of fractures.

Ibandronate sodium hydrate binds to bone mineral surfaces and is taken up by osteoclasts during bone resorption. It inhibits the mevalonate pathway, causing osteoclast apoptosis and thereby decreasing bone resorption, which helps maintain bone density.

The specific dose and infusion schedule are determined by the prescribing physician based on the patient’s clinical condition, renal function, and treatment goals. Dosage details are provided in the product’s prescribing information.

The safety of ibandronate sodium hydrate in pregnancy or while breastfeeding has not been established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and this decision must be made by a qualified healthcare professional.

To request Ossica, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Ossica is an intravenous bisphosphonate, offering a convenient once‑yearly or once‑every‑three‑months dosing schedule compared with oral bisphosphonates that require weekly or monthly dosing. It provides rapid suppression of bone turnover, but like all bisphosphonates, it shares similar safety considerations such as renal monitoring and rare risks of jaw osteonecrosis.

Ossica should be stored at ambient temperature, protected from light and moisture, and kept in its original packaging until use. Do not freeze the solution, and ensure the vial is inspected for particulate matter before administration.

Ossica is given as an intravenous infusion over a short period, typically 15‑30 minutes, under the supervision of a qualified healthcare professional. The infusion rate and total volume are defined in the prescribing information and must be followed precisely.

Serious risks include osteonecrosis of the jaw, atypical femoral fractures, severe hypocalcemia, acute renal impairment, and rare hypersensitivity reactions. Patients should be monitored for signs of these conditions, and appropriate preventive measures such as dental assessment and renal function testing are recommended.

Ossica is contraindicated in patients with severe renal impairment (creatinine clearance <30 mL/min), known hypersensitivity to ibandronate or any component of the formulation, and those with existing osteonecrosis of the jaw. Caution is advised for patients with uncontrolled hypocalcemia or active dental problems.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 09 Oct 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.